ConductScience.org, home

Paper20100967

Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.

Friedel G and 15 others. J Clin Oncol, 2010. Cited by 65 papers, by iCite.

Cite this record

ConductScience Library. Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study. Papers, record 20100967. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20100967

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Phase II trial of a trimodality regimen for stage III non-small-cell lung cancer using chemotherapy as induction treatment with concurrent hyperfractionated chemoradiation with carboplatin and paclitaxel followed by subsequent resection: a single-center study.
PubMed
Journal
J Clin Oncol
PubMed
Year
2010
PubMed
Publication types
Clinical Trial, Phase II, Journal Article
PubMed
Citations, by iCite
65
iCite
Relative citation ratio, by iCite
1.55
iCite
Revised in PubMed
2022-03-18
PubMed

Authors16

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Friedel GGodehard
2Budach WWilfried
3Dippon JJuergen
4Spengler WWerner
5Eschmann SMSusanne Martina
6Pfannenberg CChristina
7Al-Kamash FFawaz
8Walles TThorsten
9Aebert HHermann
10Kyriss TThomas
11Veit SStefanie
12Kimmich MMartin
13Bamberg MMichael
14Kohlhaeufl MMartin
15Steger VVolker
16Hehr TThomas

Source PubMed

Download CSV of authors

Topics23

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Carcinoma, Non-Small-Cell LungMajor topic
Dose Fractionation, RadiationMajor topic
Lung NeoplasmsMajor topic
Neoplasm Recurrence, LocalMajor topic
ThoracotomyMajor topic
Adolescent
Adult
Aged
Carboplatin
Combined Modality Therapy
Female
Humans
Male
Middle Aged
Neoadjuvant Therapy
Neoplasm Staging
Paclitaxel
Prognosis
Remission Induction
Survival Rate
Treatment Outcome
Young Adult

Source PubMed

Download CSV of topics

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in21205753Trimodality therapy for locally advanced non-small-cell lung cancer: a curative approach.https://conductscience.org/library/papers/21205753

Source PubMed

Download CSV of comments and corrections

Cited by31

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 65 citations.

PMIDTitleJournalYearIn PapersSource
39199656Perioperative Predictive Factors for Tumor Regression and Survival in Non-Small Cell Lung Cancer Patients Undergoing Neoadjuvant Treatment and Lung Resection.Cancers (Basel)2024https://conductscience.org/library/papers/39199656PubMed
36975452Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.Curr Oncol2023https://conductscience.org/library/papers/36975452PubMed
36672363VATS versus Open Lobectomy following Induction Therapy for Stage III NSCLC: A Propensity Score-Matched Analysis.Cancers (Basel)2023https://conductscience.org/library/papers/36672363PubMed
34776459Real-World Effectiveness and Prognostic Factors Analysis of Stages I-III Non-Small Cell Lung Cancer Following Neoadjuvant Chemo-Immunotherapy or Neoadjuvant Chemotherapy.Ann Thorac Cardiovasc Surg2022https://conductscience.org/library/papers/34776459PubMed
34104514Evaluation of prognostic factors in lung cancers with surgical complete response after induction treatment.Turk Gogus Kalp Damar Cerrahisi Derg2021https://conductscience.org/library/papers/34104514PubMed
33449266Survival analysis of pathological complete response of locally advanced lung cancer after neoadjuvant treatment.Gen Thorac Cardiovasc Surg2021https://conductscience.org/library/papers/33449266PubMed
33265905Prognostic Factors and Long-Term Survival in Locally Advanced NSCLC with Pathological Complete Response after Surgical Resection Following Neoadjuvant Therapy.Cancers (Basel)2020https://conductscience.org/library/papers/33265905PubMed
32722386Resectable IIIA-N2 Non-Small-Cell Lung Cancer (NSCLC): In Search for the Proper Treatment.Cancers (Basel)2020https://conductscience.org/library/papers/32722386PubMed
32642168Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery.J Thorac Dis2020https://conductscience.org/library/papers/32642168PubMed
30778734Keys to successful induction chemoradiotherapy followed by surgery for stage III/N2 non-small cell lung cancer.Surg Today2019https://conductscience.org/library/papers/30778734PubMed
30725275Non-small cell lung cancer with pathological complete response: predictive factors and surgical outcomes.Gen Thorac Cardiovasc Surg2019https://conductscience.org/library/papers/30725275PubMed
30626407Trimodally treatment for stage IIIa NSCLC patients increases survival while not effecting surgical mortality or complexity.J Cardiothorac Surg2019https://conductscience.org/library/papers/30626407PubMed
30083866Surgical outcomes and complications of pneumonectomy after induction therapy for non-small cell lung cancer.Gen Thorac Cardiovasc Surg2018https://conductscience.org/library/papers/30083866PubMed
29997942Pathologic complete response after induction therapy-the role of surgery in stage IIIA/B locally advanced non-small cell lung cancer.J Thorac Dis2018https://conductscience.org/library/papers/29997942PubMed
28932596Examining the ınterval between radiation therapy and surgery in trimodality therapy: Try Tri Again.J Thorac Dis2017https://conductscience.org/library/papers/28932596PubMed
28426673Lymph node volume predicts survival but not nodal clearance in Stage IIIA-IIIB NSCLC.PLoS One2017https://conductscience.org/library/papers/28426673PubMed
27358568Effectiveness of a thoracic multidisciplinary clinic in the treatment of stage III non-small-cell lung cancer.J Multidiscip Healthc2016https://conductscience.org/library/papers/27358568PubMed
26846419Preceding bronchial cutting for exposure of the pulmonary artery buried in scar tissue after chemoradiotherapy.Gen Thorac Cardiovasc Surg2017https://conductscience.org/library/papers/26846419PubMed
26410162Pneumonectomy for Clinical Stage IIIA Non-Small Cell Lung Cancer: The Effect of Neoadjuvant Therapy.Ann Thorac Surg2016https://conductscience.org/library/papers/26410162PubMed
26319488The Role of Surgical Resection in Stage IIIA Non-Small Cell Lung Cancer: A Decision and Cost-Effectiveness Analysis.Ann Thorac Surg2015https://conductscience.org/library/papers/26319488PubMed

See all 31 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/20100967

GET https://conductscience.org/api/papers/v1/20100967/cited_by?page=2